Skip to main content
SpringerLink
Log in

Effect of Government Regulation on the Evolution of Sports Nutrition

  • Chapter
Nutritional Supplements in Sports and Exercise

Abstract

The sports nutrition segment of the dietary supplement industry enjoyed over a decade of unfettered growth under federal legislation passed in 1994. A series of breakthroughs in the dietary supplement field led to the development and marketing of innovative products designed to enhance performance, build muscle, or lose excess fat. As the popularity of these products soared and evolved into a multibillion dollar industry, the sports nutrition supplement market drew the attention of federal and state regulatory bodies and sports anti-doping authorities. Growing concerns over potential consumer health risks, banned substance contamination, and unfair athletic advantages have spurred government regulators and legislators to heighten the scrutiny of this market in recent years, leading to legislative amendments and increased government enforcement action.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pub. L. No. 75–717, 52 Stat. 1040 (1938) [codified as amended 21 U.S.C. 301 et seq. (1994)].

    Google Scholar 

  2. Id., citing Senate Report No. 103–410, 103d Congress, 2d Session, Committee on Labor and Human Resources (October 8, 1994), at page 16.

    Google Scholar 

  3. Id., citing Senate Report No. 103–410, at page 22.

    Google Scholar 

  4. Provided that the Secretary then initiates on-the-record rulemaking to affirm or withdraw the declaration. See 21 U.S.C. § 342(f)(1).

    Google Scholar 

  5. 21 U.S.C. § 331(a) and (v).

    Google Scholar 

  6. 21 U.S.C. §§ 342(f)(1), 350b(a).

    Google Scholar 

  7. 21 U.S.C. § 342(f)(1)(A).

    Google Scholar 

  8. 21 U.S.C. § 333(a)(1).

    Google Scholar 

  9. 21 U.S.C. § 333(a)(2).

    Google Scholar 

  10. A “dietary ingredient” may be a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of these. See 21 U.S.C. 321 (ff)(1).

    Google Scholar 

  11. 21 U.S.C. § 350b(d).

    Google Scholar 

  12. 21 U.S.C. § 350b(a).

    Google Scholar 

  13. See FDA, Center for Food Safety & Applied Nutrition (CFSAN), New dietary ingredients in dietary supplements. Available at http://www.fda.gov/food/dietarysupplements/ucm109764.htm; see also, 21 CFR § 190.6.

  14. “To date, we have not published guidance defining the specific information that the submission must contain. Thus, you are responsible for determining what information provides the basis for your conclusion.” FDA, CFSAN, New Dietary Ingredients in Dietary Supplements, archived at http://archive.today/XyhTR.

  15. FDA, CFSAN, Draft guidance for industry: dietary supplements: New dietary ingredient notifications and related issues. Available at http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm257563.htm

  16. Id.

    Google Scholar 

  17. Natural Products Insider, Senators Hatch, Harkin Call for NDI Guidance Redo. Available at http://www.naturalproductsinsider.com/news/2012/01/senators-hatch-harkin-call-for-ndi-guidance-redo.aspx

  18. FDA, CFSAN, 95S-0316: 75-Day premarket notifications for new dietary ingredients. Available at http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s0316.htm

  19. FDA, CFSAN, FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108242.htm

  20. FDA, CFSAN, DMAA in dietary supplements. Available at http://www.fda.gov/food/dietarysupplements/qadietarysupplements/ucm346576.htm

  21. Id.

    Google Scholar 

  22. FDA, CFSAN, HHS launches crackdown on products containing andro. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/ucm108262.htm

  23. See, e.g., FDA, CFSAN, Scientific fitness androstenedione warning letter. Available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm170182.htm

  24. FDA, CFSAN, 95S-0316: 75-day premarket notifications for new dietary ingredients. Available at http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s0316.htm

  25. Siegner W. FDA’s actions on ephedra and androstenedione: understanding how they erode the protections of DSHEA. Paper presented at FDLI’s 47th Annual Conference, April 2004.

    Google Scholar 

  26. Johnson SK, Lewis PE, Inskeep EK. Steroids and cAMP in follicles of postpartum beef cows treated with norgestomet. J Anim Sci 1991;69:3747–3753. Braden TD, King ME, Odde KG, Niswender GD. Development of preovulatory follicles expected to form short-lived corpora lutea in beef cows. J Reprod Fertil 1989;85:97–104. Wise TH, Caton D, Thatcher WW, Lehrer AR, Fields MJ. Androstenedione, dehydroepiandrosterone and testosterone in ovarian vein plasma and androstenedione in peripheral arterial plasma during the bovine oestrous cycle. J Reprod Fertil 1982;66:513–518.

    Google Scholar 

  27. Margolis M. Dietary supplements: caveat athlete. Available at http://www.law.uh.edu/healthlaw/perspectives/Food/980910Dietary.html

  28. FDA, CFSAN, New dietary ingredients in dietary supplements. Archived at http://archive.today/XyhTR

  29. See FDA, CFSAN, Unlimited nutrition warning letter. Available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm225605.htm

  30. See, e.g., Oliveira v. United States Anti-Doping Agency, Court of Arbitration for Sport, CAS 2010/A/2107, available at http://www.usada.org/uploads/oliveiraCAS.pdf; United States Anti-Doping Agency (USADA), Supplement Red Flags, available at http://www.usada.org/uploads/redflagspdf.pdf; USADA, Supplement 411: The Anti-Doping Authority’s Dilemma, available at http://www.usada.org/supplement411/supplement-dilemma/anti-doping-authoritys-dilemma; Christopher Chavez, Asafa Powell Suspended, available at http://www.flotrack.org/coverage/251077-News-from-the-Track-and-Field-World/article/26098-Asafa-Powell-suspended#.U1lmg2dOUpF

  31. See generally, Legislation to Amend the Controlled Substances Act (Anabolic Steroids): Hearings on H.R. 3216 Before the Subcomm. on Crime of the House of Representatives Comm. on the Judiciary, 100th Cong., 2d Sess. 99, July 27, 1988; Steroids in Amateur and Professional Sports—The Medical and Social Costs of Steroid Abuse: Hearings Before the Senate Comm. on the Judiciary, 101st Cong. 1st Sess 736, April 3 and May 9, 1989; Abuse of Steroids in Amateur and Professional Athletics: Hearings Before the Subcomm. on Crime of the House Comm. on the Judiciary, 101st Cong., 2d Sess. 92, March 22, 1990; Hearings on H.R. 4658 Before the Subcomm. on Crime of the House Comm. on the Judiciary, 101st Cong., 2 nd Sess. 90, May 17, 1990.

    Google Scholar 

  32. Pursuant to 21 U.S.C. 812(b), a substance in Schedule III is to be placed there if: (A) the drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II; (B) the drug or other substance has a currently accepted medical use in treatment in the United States; and (C) abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.

    Google Scholar 

  33. John Burge, Legalize and regulate: a prescription for reforming anabolic steroid legislation, 15 Loy. L.A. Ent. L.J., 33, 45 (1994).

    Google Scholar 

  34. Pub. L. No. 101–647, Sec. 1902, 104 Stat. 4851 (1990).

    Google Scholar 

  35. Revised schedules are published in the Code of Federal Regulations, Part 1308 of Title 21, Food and Drugs.

    Google Scholar 

  36. 21 U.S.C. § 844.

    Google Scholar 

  37. 21 U.S.C. § 841(b)(1)(D).

    Google Scholar 

  38. For a comprehensive examination of the 1990 steroid legislation, see this co-author’s treatise, Legal Muscle: Anabolics in America (2002).

    Google Scholar 

  39. Androstenedione or “andro,” a precursor to the sex hormone testosterone, achieved national notoriety in 1998 when a bottle of the pills was spotted in the locker of St. Louis Cardinals slugger Mark McGwire.

    Google Scholar 

  40. Norsteroid prohormones, for example, can result in a positive test for nandrolone because both nandrolone and the norsteroid prohormones give rise to the urinary excretion of the metabolites norandrostenedione and norandrostenediol.

    Google Scholar 

  41. The problem of positive doping results from cross-contamination made national headlines when U.S. bobsledder Pavle Jovanovic was disqualified from the Salt Lake City Olympics for a test result he blamed on a cross-contaminated protein powder supplement and when research conducted at an IOC-accredited drug testing laboratory in 2002 found that 94 of the 634 samples contained substances not listed on the label that would trigger positive drug tests.

    Google Scholar 

  42. Examples: Anabolic Steroid Penalties: Hearings on H.R. 3866 Before the Subcomm. on Crime of the House of Representatives Comm. on the Judiciary, 108th Cong., 2 nd Sess., March 16, 2004; Consolidating Terrorist Watchlists: Hearings on H.R. 3866 Before the Subcomm. on Crime, Terrorism, and Homeland Security, House of Representatives Comm. On the Judiciary, 108th Cong., 2 nd Sess., March 25, 2004; Anabolic Steroid Control Act of 2004: Hearings on S. 2195 Before the Senate Comm. on the Judiciary, 108th Cong., 2 nd Sess., October 6th, 2004.

    Google Scholar 

  43. Public L. No. 108–358; 118 Stat. 1661 (2004).

    Google Scholar 

  44. The new compounds are androstanediol; androstanedione; androstenediol; androstenedione; bolasterone; calusterone; *1-dihydrotestosterone (a.k.a. “1-testosterone”); furazabol; 13β-ethyl-17α-hydroxygon-4-en-3-one; 4-hydroxytestosterone; 4-hydroxy-19-nortestosterone; mestanolone; 17α-methyl-3β,17β-dihydroxy-5α-androstane; 17α-methyl-3α,17β-dihydroxy-5α-androstane; 17α-methyl-3β,17β-dihydroxyandrost-4-ene; 17α-methyl-4-hydroxynandrolone; methyldienolone; methyltrienolone; 17α-methyl-*1-dihydrotestosterone (a.k.a. “17α-methyl-1-testosterone”); norandrostenediol; norandrostenedione; norbolethone; norclostebol; normethandrolone; stenbolone; and tetrahydrogestrinone.

    Google Scholar 

  45. 21 U.S.C. § 811.

    Google Scholar 

  46. Note that litigation may be required to explore what “pharmacologically related” means with respect to steroidal compounds, including whether a steroid’s anabolic capacity is inherent to its pharmacologic effect.

    Google Scholar 

  47. DHEA, or dehydroepiandrosterone, is a steroid hormone that serves as a metabolic precursor to the sex hormones estrogen and testosterone. It has become a popular dietary supplement among middle-aged and elderly consumers seeking improved vigor.

    Google Scholar 

  48. The errors in the 1990 law were exposed by coauthor Collins in Legal Muscle (see endnote 38). However, at least one typographic error appears in the new law: 13α-ethyl-17α-hydroxygon-4-en-3-one (a demethylated version of norbolethone) should read as 13β-ethyl-17β-hydroxygon-4-en-3-one. A new bill [S. 893] was introduced on April 25, 2005 to fix the problem (it also amends the chemical nomenclature for stanozolol).

    Google Scholar 

  49. The definition of an anabolic steroid under the old law included, under subparagraph (xxviii), is “any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt ester, or isomer promotes muscle growth.” The new law says, “any salt, ester, or ether of a drug or substance described in this paragraph.” Note that the reference to muscle growth in the old law has been omitted [from what is now, in the longer list, subparagraph (xlx) of the new law] and that the word “isomer” has been replaced by “ether.”

    Google Scholar 

  50. Classification of three steroids as schedule III anabolic steroids under the controlled substances act, 74 Fed. Reg. 63,603 (Dec. 4, 2009) (codified at 21 C.F.R. pt. 1300). Available at http://www.gpo.gov/fdsys/pkg/FR-2009-12-04/pdf/E9-28572.pdf

  51. Classification of two steroids, prostanozol and methasterone, as schedule III anabolic steroids under the controlled substances act, 77 Fed. Reg. 44,456 (July 30, 2012) (codified at 21 C.F.R. pt. 1300), available at (http://www.gpo.gov/fdsys/pkg/FR-2012-07-30/pdf/2012-18495.pdf).

  52. Public L. No. 113-260 128 STAT. 2929 (2014).

    Google Scholar 

  53. See, e.g., FDA, Office of Criminal Investigations, May 22, 2012: Bodybuilding.com, LLC and Jeremy DeLuca Plead Guilty in Federal Court to Violating FDCA. Available at http://www.fda.gov/ICECI/CriminalInvestigations/ucm305494.htm.

  54. Gilroy DJ, et al. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environ Health Perspect. 2000;108:435–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Department of Health & Human Services, Centers for Disease Control & Prevention, Facts about cyanobacteria & cyanobacterial harmful algal blooms. Available at www.cdc.gov/hab/cyanobacteria/pdfs/facts.pdf

  56. FDA, CFSAN, Guidance for industry: substantiation for dietary supplement claims made under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act. Available at http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm073200.htm

  57. FDA, CFSAN, Guidance for industry: structure/function claims, small entity compliance guide. Available at http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm103340.htm

  58. Correia EW. The federal trade commission’s regulation of weight loss advertising claims. Food Drug Law J. 2004;59(4).

    Google Scholar 

  59. Federal Trade Commission (FTC), Bureau of Consumer Protection Business Center, Dietary Supplements: an advertising guide for industry. Available at http://www.business.ftc.gov/documents/bus09-dietary-supplements-advertising-guide-industry

  60. FTC, gut check: a reference guide for media on spotting false weight loss claims. Available at http://www.business.ftc.gov/documents/0492-gut-check-reference-guide-media-spotting-false-weight-loss-claims

  61. 15 USC 45(a)(1)(2000).

    Google Scholar 

  62. FTC, FTC Policy Statement Regarding Advertising Substantiation, available at http://www.ftc.gov/ftc-policy-statement-regarding-advertising-substantiation; see In re Thompson Medical Co., 104 F.T.C. 648 (1984), aff’d, 791 F.2d 189 (D.C. Cir. 1986).

  63. In re Pfizer, Inc., 81 F.T.C. 23 (1972).

    Google Scholar 

  64. POM Wonderful LLC v. F.T.C., 894 F. Supp. 2d 40 (2012).

    Google Scholar 

  65. FTC, Bureau of Consumer Protection Business Center, Dietary supplements: an advertising guide for industry. Available at http://www.business.ftc.gov/documents/bus09-dietary-supplements-advertising-guide-industry

  66. In re Schering Corp., 118 FTC 1030, 1123, 1127 (1994).

    Google Scholar 

  67. FTC, FTC concludes case against marketers of xenadrine efx; court ruling requires final defendant to accept settlement terms. Available at http://www.ftc.gov/news-events/press-releases/2009/04/ftc-concludes-case-against-marketers-xenadrine-efx-court-ruling

  68. FTC, Florida man settles FTC charges of sending illegal spam and making false “human growth hormone” product claims. Available at http://www.ftc.gov/news-events/press-releases/2005/06/florida-man-settles-ftc-charges-sending-illegal-spam-and-making

  69. FTC, FTC targets bogus anti-aging claims for pills and sprays promising human growth hormone benefits. Available at http://www.ftc.gov/news-events/press-releases/2005/06/ftc-targets-bogus-anti-aging-claims-pills-and-sprays-promising

  70. FTC, FTC settles claims with marketers of FiberThin and Propolene. Available at http://www.ftc.gov/news-events/press-releases/2005/06/ftc-settles-claims-marketers-fiberthin-and-propolene

  71. FTC, defendants who deceptively marketed the himalayan diet breakthrough settle FTC charges. Available at http://www.ftc.gov/news-events/press-releases/2005/06/defendants-who-deceptively-marketed-himalayan-diet-breakthrough

Download references

Author information

Authors and Affiliations

  1. Collins, McDonald & Gann, P.C., 138 Mineola Boulevard, Mineola, NY, 11501, USA

    Rick Collins ESQ, JD, FISSN

  2. Florida International University, Miami, FL, 33199, USA

    Douglas S. Kalman PhD, RD, CCRC, FISSN, FACN

Authors
  1. Rick Collins ESQ, JD, FISSN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas S. Kalman PhD, RD, CCRC, FISSN, FACN
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rick Collins ESQ, JD, FISSN .

Editor information

Editors and Affiliations

  1. Exercise Sport Nutrition Laboratory, Department of Health & Kinesiology, Texas A & M University, College Station, Texas, USA

    Mike Greenwood

  2. Biomedical and Lifestyle Diseases (BioLED) Unit, Institute of Sport, Exercise & Active Living, College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia

    Matthew B. Cooke

  3. The Center For Applied Health Sciences (CAHS), Stow, Ohio, USA

    Tim Ziegenfuss

  4. Nutrition & Applied Clinical Trials, QPS-MRA (Miami Research) & Athletics Department, Florida International University, Miami, Florida, USA

    Douglas S. Kalman

  5. Exercise & Sport Science Laboratory, Nova Southeastern University, Fort Lauderdale-Davie, Florida, USA

    Jose Antonio

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Collins, R., Kalman, D.S. (2015). Effect of Government Regulation on the Evolution of Sports Nutrition. In: Greenwood, M., Cooke, M., Ziegenfuss, T., Kalman, D., Antonio, J. (eds) Nutritional Supplements in Sports and Exercise. Springer, Cham. https://doi.org/10.1007/978-3-319-18230-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18230-8_1

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18229-2

  • Online ISBN: 978-3-319-18230-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation